ArticleMedicare & medicaid research review2011
Endocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare Part D.
Article in Medicare & medicaid research review, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- A systematic review of interventions to improve adherence to endocrine therapy.Breast cancer research and treatment · 2019Pooled it
- Racial/Ethnic and socioeconomic disparities in endocrine therapy adherence in breast cancer: a systematic review.American journal of public health · 2015Pooled it
- Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review.Breast cancer research and treatment · 2012Pooled it
- Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer.BMC cancer · 2022Trial
- Association between low-income subsidies and inequities in orally administered antimyeloma therapy use.The American journal of managed care · 2023Article
- Association of Endocrine Therapy Initiation Timeliness With Adherence and Continuation in Low-Income Women With Breast Cancer.JAMA network open · 2022Article
- Article
- Octogenarians' Breast Cancer Is Associated with an Unfavorable Tumor Immune Microenvironment and Worse Disease-Free Survival.Cancers · 2021Article
- Cost sharing for breast cancer hormone therapy: How do dual eligible patients' copayment impact adherence.PloS one · 2021Article
- Predicting adjuvant endocrine therapy initiation and adherence among older women with early-stage breast cancer.Breast cancer research and treatment · 2020Article
- Racial and Geographic Disparities in Endocrine Therapy Adherence Among Younger Breast Cancer Survivors.American journal of clinical oncology · 2020Article
- The impact of generic aromatase inhibitors on initiation, adherence, and persistence among women with breast cancer: Applying multi-state models to understand the dynamics of adherence.Pharmacoepidemiology and drug safety · 2020Article
- Patient and provider perspectives on delivery of oral cancer therapies.Patient education and counseling · 2019Article
- Racial Disparities in Breast Cancer Outcomes in the Metropolitan Atlanta Area: New Insights and Approaches for Health Equity.JNCI cancer spectrum · 2019Article
- Article
- Fractures in a nationwide population-based cohort of users of breast cancer hormonal therapy.Journal of cancer survivorship : research and practice · 2018Article
- Current Strategies of Endocrine Therapy in Elderly Patients with Breast Cancer.BioMed research international · 2018Review
- Socioeconomic status and breast cancer treatment.Breast cancer research and treatment · 2018Review
- Recent Trends in Cost-Related Medication Nonadherence Among Cancer Survivors in the United States.Journal of managed care & specialty pharmacy · 2018Article
- Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States.JAMA oncology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClinical guidelines recommend that women with hormone-receptor positive breast cancer receive endocrine therapy (selective estrogen receptor modulators [SERMs] or aromatase inhibitors [AIs]) for five years following diagnosis.
objectiveTo examine utilization and adherence to therapy for SERMs and AIs in Medicare Part D prescription drug plans. DATA: Linked Surveillance, Epidemiology, and End Results (SEER)-Medicare data. STUDY
designWe identified 15,542 elderly women diagnosed with hormone-receptor positive breast cancer in years 2003-2005 (the latest SEER data at the time of the study) and enrolled in a Part D plan in 2006 or 2007 (the initial years of Part D). This permitted us to compare utilization and adherence to therapy at various points within the recommended five-year timeframe for endocrine therapy. SERM and AI use was measured from claim records. Non-adherence to therapy was defined as a medication possession ratio of less than 80 percent. PRINCIPAL
findingsBetween May 2006 and December 2007, 22 percent of beneficiaries received SERM, 52 percent AI, and 26 percent received neither. The percent receiving any endocrine therapy decreased with time from diagnosis. Among SERM and AI users, 20-30 percent were non-adherent to therapy; out-of-pocket costs were higher for AI than SERM and were strongly associated with non-adherence. For AI users without a low income subsidy, adherence to therapy deteriorated after reaching the Part D coverage gap.
conclusionsMany elderly breast cancer patients were not receiving therapy for the recommended five years following diagnosis. Choosing a Part D plan that minimizes out-of-pocket costs is critical to ensuring beneficiary access to essential medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.